| Name | Title | Contact Details |
|---|
Accuro Medical Products is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Water Lens is an innovative company that is revolutionizing the $10B water testing industry. We have developed a system for real-time chemical analysis of water and other fluids, on location, for industries that use large amounts of water (e.g., oil and gas, agriculture, power generation, coal mining, and food processing).
Integrated Health Network (IHN) of Wisconsin is the state’s first multi-system, clinically integrated accountable care network and one of the first in the United States. It is a consortium of independent health systems, hospitals and physicians working together to improve the quality, efficiency and value of health care. Since its launch in 2010, IHN has been transforming health care delivery with our clinically integrated network of leading health care providers and our sophisticated infrastructure for data analytics. The result is a model that delivers high quality health care and the cost savings of a narrow network, combined with the scale and value only possible through the breadth of a larger system.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology.